<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: oa--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">14562014</article-id><article-id pub-id-type="pmc">2394343</article-id><article-id pub-id-type="pii">6601310</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6601310</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical</subject></subj-group></article-categories><title-group><article-title>Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Aparicio</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Desram&#x000e9;</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lecomte</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Mitry</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Belloc</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Etienney</surname><given-names>I</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Montembault</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Vayre</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Locher</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Ezenfis</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Artru</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Mabro</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Dominguez</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff12">12</xref></contrib></contrib-group><aff id="aff1"><label>1</label><sup>1</sup>Service d'H&#x000e9;pato-Gastroent&#x000e9;rologie, H&#x000f4;pital Bichat-Claude Bernard, 46 rue Henri Huchard, AP-HP, Paris 75018, France</aff><aff id="aff2"><label>2</label><sup>2</sup>Clinique m&#x000e9;dicale, H&#x000f4;pital d'instruction des arm&#x000e9;es du Val de Gr&#x000e2;ce, Paris 75005, France</aff><aff id="aff3"><label>3</label><sup>3</sup>Service d'H&#x000e9;pato-Gastroent&#x000e9;rologie, H&#x000f4;pital Europ&#x000e9;en Georges Pompidou, AP-HP, Paris 75015, France</aff><aff id="aff4"><label>4</label><sup>4</sup>Service d'H&#x000e9;pato-Gastroent&#x000e9;rologie, H&#x000f4;pital Ambroise Par&#x000e9;, AP-HP, Boulogne 92100, France</aff><aff id="aff5"><label>5</label><sup>5</sup>Service d'H&#x000e9;pato-Gastroent&#x000e9;rologie, Institut Gustave Roussy, Villejuif 94805, France</aff><aff id="aff6"><label>6</label><sup>6</sup>Service d'H&#x000e9;pato-Gastroent&#x000e9;rologie, H&#x000f4;pital de Soissons, Soissons 02200, France</aff><aff id="aff7"><label>7</label><sup>7</sup>Service d'H&#x000e9;pato-Gastroent&#x000e9;rologie, H&#x000f4;pital Cochin, AP-HP, Paris 75005, France</aff><aff id="aff8"><label>8</label><sup>8</sup>Service d'H&#x000e9;pato-Gastroent&#x000e9;rologie, H&#x000f4;pital Henri Mondor, AP-HP, Cr&#x000e9;teil 94000, France</aff><aff id="aff9"><label>9</label><sup>9</sup>Service d'H&#x000e9;pato-Gastroent&#x000e9;rologie, H&#x000f4;pital de Longjumeau, Longjumeau 91600, France</aff><aff id="aff10"><label>10</label><sup>10</sup>Service d'Oncologie, H&#x000f4;pital Saint Antoine, AP-HP, Paris 75011, France</aff><aff id="aff11"><label>11</label><sup>11</sup>Service d'Oncologie, H&#x000f4;pital Foch, Suresnes 92150, France</aff><aff id="aff12"><label>12</label><sup>12</sup>D&#x000e9;partement Uro-Digestif, Centre Oscar Lambret, Lille 59020, France</aff><aff id="aff13"><label>13</label><sup>13</sup>AGEO: &#x02018;Association des gastroent&#x000e9;rologues oncologues&#x02019; 26 Avenue des Gobelins, Paris 75013, France</aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:thomas.aparicio@bch.ap-hop-paris.fr">thomas.aparicio@bch.ap-hop-paris.fr</email></corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>10</month><year>2003</year></pub-date><pub-date pub-type="ppub"><day>20</day><month>10</month><year>2003</year></pub-date><volume>89</volume><issue>8</issue><fpage>1439</fpage><lpage>1444</lpage><history><date date-type="received"><day>12</day><month>06</month><year>2003</year></date><date date-type="rev-recd"><day>11</day><month>08</month><year>2003</year></date><date date-type="accepted"><day>12</day><month>08</month><year>2003</year></date></history><copyright-statement>Copyright 2003, Cancer Research UK</copyright-statement><copyright-year>2003</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><kwd-group><kwd>colon cancer</kwd><kwd>elderly</kwd><kwd>chemotherapy</kwd><kwd>oxaliplatin</kwd><kwd>irinotecan</kwd></kwd-group></article-meta></front><body><p>Colorectal cancer is the second most frequent cancer in Europe (<xref ref-type="other" rid="bib3">Bray <italic>et al</italic>, 2002</xref>) and 40&#x00025; of patients are of age 74 years and more at diagnosis (<xref ref-type="other" rid="bib12">Gatta <italic>et al</italic>, 1998</xref>). Nevertheless, patients over 75 years have been usually excluded from randomised clinical trials evaluating chemotherapy for advanced colorectal cancer (<xref ref-type="other" rid="bib23">Trimble <italic>et al</italic>, 1994</xref>; <xref ref-type="other" rid="bib13">Kohne <italic>et al</italic>, 2001</xref>). Few data are available on chemotherapy in elderly patients, but it has been suggested that 5-fluorouracil (5-FU)-based chemotherapy efficacy was comparable to that in younger patients (<xref ref-type="other" rid="bib22">Stein <italic>et al</italic>, 1995</xref>; <xref ref-type="other" rid="bib5">Chiara <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib14">Mabro <italic>et al</italic>., 1999</xref>; <xref ref-type="other" rid="bib18">Popescu <italic>et al</italic>., 1999</xref>; <xref ref-type="other" rid="bib15">Magne <italic>et al</italic>., 2002</xref>). Tolerance was comparable except in one study evaluating chemotherapy with bolus 5-FU (<xref ref-type="other" rid="bib22">Stein <italic>et al</italic>, 1995</xref>). A survival benefit was demonstrated in one unpublished randomised study comparing 5-FU-based chemotherapy to best supportive care in elderly patients (<xref ref-type="other" rid="bib2">Beretta <italic>et al</italic>, 1997</xref>). In the adjuvant setting, a pooled analysis of randomised trials with 5-FU-based chemotherapy confirmed the improvement of disease-free survival and overall survival (OS) with chemotherapy, even in patients over 70 years (<xref ref-type="other" rid="bib21">Sargent <italic>et al</italic>, 2001</xref>).</p><p>Oxaliplatin (<xref ref-type="other" rid="bib7">de Gramont <italic>et al</italic>, 2000</xref>) and irinotecan (<xref ref-type="other" rid="bib9">Douillard <italic>et al</italic>, 2000</xref>), in combination with 5-FU&#x02013;leucovorin, have demonstrated their efficacy in advanced colorectal cancer with a better tumour response rate than 5-FU and leucovorin alone. After 5-FU failure, irinotecan as second-line chemotherapy has demonstrated a survival advantage compared to best supportive care in advanced colorectal cancer (<xref ref-type="other" rid="bib6">Cunningham <italic>et al</italic>, 1998</xref>). Combination therapy, however, has an increased toxicity compared to 5-FU alone, especially neutropenia, diarrhoea and neurologic toxicity with oxaliplatin and neutropenia, and diarrhoea with irinotecan.</p><p>No data from clinical trials are available about chemotherapy with oxaliplatin or irinotecan in patients aged 75 years and more with advanced colorectal cancer. We report the result of tolerance and efficacy of oxaliplatin- or irinotecan-based chemotherapy in a multicentre observational cohort of patients of age 75 years and more with an advanced colorectal cancer.</p><sec sec-type="methods"><title>PATIENTS AND METHODS</title><sec><title>Patients</title><p>Data were collected from 12 centres. Each investigator included all consecutives patients over 74 years treated with oxaliplatin or irinotecan for advanced colorectal carcinoma from January 1999 to June 2002. All patients had a histologically proven colorectal adenocarcinoma. All the regimens containing oxaliplatin or irinotecan were considered either in association with 5-FU&#x0002f;leucovorin, oral 5-FU or raltitrexed. Only the first regimen was considered for evaluation in patients receiving both oxaliplatin and irinotecan sequentially. Patients were divided into two groups: group 1 patients 75&#x02013;79 years old and group 2 patients 80 years old and over. The following clinical and biological variables were recorded: age, sex, body mass index, primary localisation, sites of metastasis, World Health Organisation (WHO) performance status (PS), Charlson comorbidity score (<xref ref-type="other" rid="bib4">Charlson <italic>et al</italic>, 1987</xref>), haemoglobin, creatinin clearance (according to Cockroft method), alkaline phosphatase and carcinoembryonic antigen.</p></sec><sec><title>Chemotherapy</title><p>The chemotherapy regimens used were: FOLFOX 4 (leucovorin 200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup> as a 2-h infusion followed by bolus 5-FU 400&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup> and a 22-h 5-FU infusion of 600&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup>, repeated for 2 consecutive days every 2 weeks. Oxaliplatin 85&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> was given on day 1 as a 2-h infusion concurrent with leucovorin) (<xref ref-type="other" rid="bib7">de Gramont <italic>et al</italic>, 2000</xref>), FOLFOX 6 (oxaliplatin 100&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> was infused with leucovorin 400&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> as a 2-h infusion on day 1, followed by bolus 400&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> and a 46-h infusion 2400&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> of 5-FU, every 2 weeks) (<xref ref-type="other" rid="bib16">Maindrault-Goebel <italic>et al</italic>, 2000</xref>), FOLFOX 7 consisted of the same regimen with oxaliplatin 130&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> (<xref ref-type="other" rid="bib17">Maindrault-Goebel <italic>et al</italic>, 2001</xref>), ELOXFU-3 (leucovorin 200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> as a 2-h infusion followed by bolus 5FU 400&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> and a 48-h infusion of 2400&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> and oxaliplatin 130&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> on day 1 every 3 weeks) (<xref ref-type="other" rid="bib10">Ducreux <italic>et al</italic>, 1999</xref>), LV5FU2-irinotecan (leucovorin 200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup> as a 2-h infusion followed by bolus 5-FU 400&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup> and a 22-h 5-FU infusion of 600&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup>, repeated for 2 consecutive days every 2 weeks. Irinotecan 180&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> was given on day 1 as a 1.5-h infusion concurrent with leucovorin) (<xref ref-type="other" rid="bib9">Douillard <italic>et al</italic>, 2000</xref>).</p><p>According to evidence-based medicine, treatment was continued until disease progression or unacceptable toxicity occurred or until a patient chose to discontinue it.</p></sec><sec><title>Study parameters</title><p>When measurable, tumour response was assessed with computed tomography (CT) examination every 2&#x02013;3 months according to WHO criteria. A complete response was defined as the complete disappearance of all clinically assessable disease, and a partial response was defined as a decrease of at least 50&#x00025; of the sum of the products of the diameters of measurable lesions. Stable disease was defined as a decrease of less than 50&#x00025; or an increase of less than 25&#x00025; of measurable lesions, and progressive disease was defined as an increase of at least 25&#x00025; of measurable lesions or the appearance of new malignant lesion(s). Progression-free survival (PFS) was defined as the time interval from the beginning of oxaliplatin- or irinotecan-based chemotherapy to the date of disease progression or, if the patient died without evidence of progression, to the date of death. OS lasted from the date of the beginning of oxaliplatin- or irinotecan-based chemotherapy to the date of death or the date when the patient was seen for the last time. Toxicities were collected at each cure according to WHO criteria.</p></sec><sec><title>Statistical analysis</title><p>Since this was not a randomised study, only patient characteristics at inclusion were statistically compared, using <italic>&#x003c7;</italic><sup>2</sup> test for categorical variables and Student's <italic>t</italic>-test for continuous variables. OS and PFS were calculated using the Kaplan&#x02013;Meier method. For all statistical tests, <italic>P</italic>-values less than or equal to 0.05 were considered significant.</p></sec></sec><sec><title>RESULTS</title><sec><title>Patients and treatment</title><p>Data from 66 consecutive patients treated from January 1999 to June 2002 were collected. Patient characteristics are presented in <xref rid="tbl1" ref-type="table">Table 1</xref>
 <table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Patient characteristics</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Patients characteristics</bold></th><th align="left" valign="top" charoff="50"><bold>All patients, <italic>n</italic>&#x0003d;66 (&#x00025;)</bold></th><th align="left" valign="top" charoff="50"><bold>Group 1, <italic>n</italic>&#x0003d;48 (&#x00025;)</bold></th><th align="left" valign="top" charoff="50"><bold>Group 2, <italic>n</italic>&#x0003d;18 (&#x00025;)</bold></th><th align="left" valign="top" charoff="50"><bold>First line, <italic>n</italic>&#x0003d;27 (&#x00025;)</bold></th><th align="left" valign="top" charoff="50"><bold>Second line, <italic>n</italic>&#x0003d;34 (&#x00025;)</bold></th></tr></thead><tbody valign="top"><tr><td colspan="6" align="left" valign="top" charoff="50"><italic>Sex</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Male</td><td align="left" valign="top" charoff="50">39 (59)</td><td align="left" valign="top" charoff="50">25 (52)</td><td align="left" valign="top" charoff="50">14 (78)<sup>&#x0002a;</sup></td><td align="left" valign="top" charoff="50">15 (56)</td><td align="left" valign="top" charoff="50">20 (59)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Female</td><td align="left" valign="top" charoff="50">27 (41)</td><td align="left" valign="top" charoff="50">23 (48)</td><td align="left" valign="top" charoff="50">4 (22)</td><td align="left" valign="top" charoff="50">12 (44)</td><td align="left" valign="top" charoff="50">14 (41)</td></tr><tr><td colspan="6" align="left" valign="top" charoff="50"><italic>Site of primary tumour</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Colon</td><td align="left" valign="top" charoff="50">52 (79)</td><td align="left" valign="top" charoff="50">38 (79)</td><td align="left" valign="top" charoff="50">14 (78)</td><td align="left" valign="top" charoff="50">20 (74)</td><td align="left" valign="top" charoff="50">27 (79)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Rectum</td><td align="left" valign="top" charoff="50">14 (21)</td><td align="left" valign="top" charoff="50">10 (21)</td><td align="left" valign="top" charoff="50">4 (22)</td><td align="left" valign="top" charoff="50">7 (26)</td><td align="left" valign="top" charoff="50">7 (21)</td></tr><tr><td colspan="6" align="left" valign="top" charoff="50"><italic>No. of metastatic site(s)</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1</td><td align="left" valign="top" charoff="50">38 (58)</td><td align="left" valign="top" charoff="50">30 (62)</td><td align="left" valign="top" charoff="50">8 (44)</td><td align="left" valign="top" charoff="50">16 (59)</td><td align="left" valign="top" charoff="50">19 (56)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2</td><td align="left" valign="top" charoff="50">19 (29)</td><td align="left" valign="top" charoff="50">11 (23)</td><td align="left" valign="top" charoff="50">8 (44)</td><td align="left" valign="top" charoff="50">8 (30)</td><td align="left" valign="top" charoff="50">10 (29)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003e;2</td><td align="left" valign="top" charoff="50">9 (14)</td><td align="left" valign="top" charoff="50">7 (15)</td><td align="left" valign="top" charoff="50">2 (12)</td><td align="left" valign="top" charoff="50">3 (11)</td><td align="left" valign="top" charoff="50">5 (15)</td></tr><tr><td colspan="6" align="left" valign="top" charoff="50"><italic>Charlson comorbidity index</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;0</td><td align="left" valign="top" charoff="50">39 (59)</td><td align="left" valign="top" charoff="50">29 (60)</td><td align="left" valign="top" charoff="50">10 (55)</td><td align="left" valign="top" charoff="50">16 (59)</td><td align="left" valign="top" charoff="50">21 (62)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1&#x02013;2</td><td align="left" valign="top" charoff="50">18 (27)</td><td align="left" valign="top" charoff="50">13 (27)</td><td align="left" valign="top" charoff="50">5 (28)</td><td align="left" valign="top" charoff="50">6 (22)</td><td align="left" valign="top" charoff="50">10 (29)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003e;2</td><td align="left" valign="top" charoff="50">9 (14)</td><td align="left" valign="top" charoff="50">6 (13)</td><td align="left" valign="top" charoff="50">3 (17)</td><td align="left" valign="top" charoff="50">5 (19)</td><td align="left" valign="top" charoff="50">3 (9)</td></tr><tr><td colspan="6" align="left" valign="top" charoff="50"><italic>Performance status</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;0</td><td align="left" valign="top" charoff="50">13 (20)</td><td align="left" valign="top" charoff="50">11 (23)</td><td align="left" valign="top" charoff="50">2 (11)</td><td align="left" valign="top" charoff="50">3 (11)</td><td align="left" valign="top" charoff="50">8 (24)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1</td><td align="left" valign="top" charoff="50">31 (47)</td><td align="left" valign="top" charoff="50">22 (46)</td><td align="left" valign="top" charoff="50">9 (50)</td><td align="left" valign="top" charoff="50">14 (52)</td><td align="left" valign="top" charoff="50">14 (41)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2</td><td align="left" valign="top" charoff="50">19 (29)</td><td align="left" valign="top" charoff="50">15 (31)</td><td align="left" valign="top" charoff="50">4 (22)</td><td align="left" valign="top" charoff="50">8 (30)</td><td align="left" valign="top" charoff="50">11 (32)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;3</td><td align="left" valign="top" charoff="50">3 (4)</td><td align="left" valign="top" charoff="50">0 (0)</td><td align="left" valign="top" charoff="50">3 (17)<sup>&#x0002a;&#x0002a;</sup></td><td align="left" valign="top" charoff="50">2 (7)</td><td align="left" valign="top" charoff="50">1 (3)</td></tr><tr><td align="left" valign="top" charoff="50">Mean creatinin clearance (ml&#x02009;min<sup>&#x02212;1</sup>)</td><td align="left" valign="top" charoff="50">58.9&#x000b1;1.8</td><td align="left" valign="top" charoff="50">61.4&#x000b1;2.1</td><td align="left" valign="top" charoff="50">52&#x000b1;3.5<sup>&#x0002a;&#x0002a;&#x0002a;</sup></td><td align="left" valign="top" charoff="50">62&#x000b1;2.5</td><td align="left" valign="top" charoff="50">57&#x000b1;2.6</td></tr><tr><td align="left" valign="top" charoff="50">Mean haemoglobin (g&#x02009;dl<sup>&#x02212;1</sup>)</td><td align="left" valign="top" charoff="50">12&#x000b1;0.2</td><td align="left" valign="top" charoff="50">11.8&#x000b1;0.2</td><td align="left" valign="top" charoff="50">12.5&#x000b1;0.3</td><td align="left" valign="top" charoff="50">11.8&#x000b1;0.2</td><td align="left" valign="top" charoff="50">12.1&#x000b1;0.3</td></tr><tr><td align="left" valign="top" charoff="50">CEA &#x0003c;5 (ng&#x02009;ml<sup>&#x02212;1</sup>)</td><td align="left" valign="top" charoff="50">11 (17)</td><td align="left" valign="top" charoff="50">9 (19)</td><td align="left" valign="top" charoff="50">2 (11)</td><td align="left" valign="top" charoff="50">5 (18)</td><td align="left" valign="top" charoff="50">6 (18)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003e;5&#x02013;50&#x02009;ng&#x02009;ml<sup>&#x02212;1</sup></td><td align="left" valign="top" charoff="50">19 (29)</td><td align="left" valign="top" charoff="50">13 (27)</td><td align="left" valign="top" charoff="50">6 (33)</td><td align="left" valign="top" charoff="50">7 (26)</td><td align="left" valign="top" charoff="50">9 (26)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003e;50&#x02009;ng&#x02009;ml<sup>&#x02212;1</sup></td><td align="left" valign="top" charoff="50">31 (47)</td><td align="left" valign="top" charoff="50">22 (46)</td><td align="left" valign="top" charoff="50">9 (50)</td><td align="left" valign="top" charoff="50">15 (56)</td><td align="left" valign="top" charoff="50">15 (44)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Not done</td><td align="left" valign="top" charoff="50">5 (7)</td><td align="left" valign="top" charoff="50">4 (8)</td><td align="left" valign="top" charoff="50">1 (6)</td><td align="left" valign="top" charoff="50">0</td><td align="left" valign="top" charoff="50">4 (12)</td></tr><tr><td colspan="6" align="left" valign="top" charoff="50"><italic>Alkaline phosphatase</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003c;<italic>N</italic></td><td align="left" valign="top" charoff="50">42 (64)</td><td align="left" valign="top" charoff="50">34 (71)</td><td align="left" valign="top" charoff="50">8 (45)</td><td align="left" valign="top" charoff="50">19 (70)</td><td align="left" valign="top" charoff="50">20 (59)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003e;<italic>N</italic>&#x02013;2<italic>N</italic></td><td align="left" valign="top" charoff="50">11 (17)</td><td align="left" valign="top" charoff="50">5 (10)</td><td align="left" valign="top" charoff="50">6 (33)</td><td align="left" valign="top" charoff="50">4 (15)</td><td align="left" valign="top" charoff="50">5 (15)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003e;2<italic>N</italic></td><td align="left" valign="top" charoff="50">10 (15)</td><td align="left" valign="top" charoff="50">6 (13)</td><td align="left" valign="top" charoff="50">4 (22)</td><td align="left" valign="top" charoff="50">4 (15)</td><td align="left" valign="top" charoff="50">6 (17)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Not done</td><td align="left" valign="top" charoff="50">3 (4)</td><td align="left" valign="top" charoff="50">3 (6)</td><td align="left" valign="top" charoff="50">0<sup>&#x0002a;&#x0002a;&#x0002a;&#x0002a;</sup></td><td align="left" valign="top" charoff="50">0</td><td align="left" valign="top" charoff="50">3 (9)</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote1"><label>&#x0002a;</label><p><italic>P</italic>&#x0003d;0.058. </p></fn><fn id="tbfnote2"><label>&#x0002a;&#x0002a;</label><p><italic>P</italic>&#x0003d;0.025. </p></fn><fn id="tbfnote3"><label>&#x0002a;&#x0002a;&#x0002a;</label><p><italic>P</italic>&#x0003d;0.04. </p></fn><fn id="tbfnote4"><label>&#x0002a;&#x0002a;&#x0002a;&#x0002a;</label><p><italic>P</italic>&#x0003d;0.044.</p></fn></table-wrap-foot></table-wrap>. The median age was 78 years (range, 75&#x02013;88 years). In all, 48 patients were 75&#x02013;79 years old (group 1) and 18 were aged 80 or over (group 2). For groups 1 and 2, the median ages were, respectively, 77 years (range, 74&#x02013;79 years) and 81 years (range, 80&#x02013;88 years). Of the 66 patients, 39 had no severe comorbidity according to the Charlson index. No significant difference for sex, site of primary tumour, number of metastasic sites and comorbidity were observed between patients of groups 1 and 2. Group 2 patients had a significantly poorer PS. Creatinin clearance was significantly lower in group 2 than in group 1 (<xref rid="tbl1" ref-type="table">Table 1</xref>). There was no significant difference in baseline characteristics between patients treated in first line and patients treated in second line (<xref rid="tbl1" ref-type="table">Table 1</xref>).</p><p>Out of the 66 patients, 44 received an oxaliplatin-based regimen and 22 received an irinotecan-based regimen. A total of 60 patients were treated with a combination of oxaliplatin or irinotecan with 5-FU&#x0002f;leucovorin (<xref rid="tbl2" ref-type="table">Table 2</xref>
 <table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p content-type="table-title">Chemotherapy characteristics</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Chemotherapy regimens</bold></th><th align="center" valign="top" charoff="50"><bold>All patients, <italic>n</italic>&#x0003d;66 (&#x00025;)</bold></th><th align="center" valign="top" charoff="50"><bold>Mean number of cycles<sup>a</sup></bold></th><th align="center" valign="top" charoff="50"><bold>Group 1, <italic>n</italic>&#x0003d;48 (&#x00025;)</bold></th><th align="center" valign="top" charoff="50"><bold>Mean number of cycle</bold></th><th align="center" valign="top" charoff="50"><bold>Group 2, <italic>n</italic>&#x0003d;18 (&#x00025;)</bold></th><th align="center" valign="top" charoff="50"><bold>Mean number of cycle</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">LV5FU2-irinotecan</td><td align="center" valign="top" charoff="50">21 (32)</td><td align="center" valign="top" charoff="50">10.9&#x000b1;1.3</td><td align="center" valign="top" charoff="50">15 (31)</td><td align="center" valign="top" charoff="50">10.7&#x000b1;1.4</td><td align="center" valign="top" charoff="50">6 (33)</td><td align="center" valign="top" charoff="50">11.5&#x000b1;3.2</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;FOLFOX 4</td><td align="center" valign="top" charoff="50">20 (30)</td><td align="center" valign="top" charoff="50">8.2&#x000b1;0.7</td><td align="center" valign="top" charoff="50">17 (36)</td><td align="center" valign="top" charoff="50">8.8&#x000b1;0.8</td><td align="center" valign="top" charoff="50">3 (17)</td><td align="center" valign="top" charoff="50">5.3&#x000b1;1.4</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;FOLFOX 6</td><td align="center" valign="top" charoff="50">12 (18)</td><td align="center" valign="top" charoff="50">7.8&#x000b1;1</td><td align="center" valign="top" charoff="50">8 (17)</td><td align="center" valign="top" charoff="50">8&#x000b1;1.4</td><td align="center" valign="top" charoff="50">4 (22)</td><td align="center" valign="top" charoff="50">7.5&#x000b1;1.8</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;ELOXFU 3</td><td align="center" valign="top" charoff="50">5 (8)</td><td align="center" valign="top" charoff="50">3.4&#x000b1;0.8</td><td align="center" valign="top" charoff="50">4 (8)</td><td align="center" valign="top" charoff="50">3.5&#x000b1;1</td><td align="center" valign="top" charoff="50">1 (6)</td><td align="char" valign="top" char="." charoff="50">3.0</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;FOLFOX 7</td><td align="center" valign="top" charoff="50">2 (3)</td><td align="center" valign="top" charoff="50">7.0&#x000b1;1</td><td align="center" valign="top" charoff="50">2 (4)</td><td align="center" valign="top" charoff="50">7.0&#x000b1;1</td><td align="center" valign="top" charoff="50">&#x02014;</td><td align="center" valign="top" charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">Oxaliplatin monotherapy</td><td align="center" valign="top" charoff="50">2 (3)</td><td align="center" valign="top" charoff="50">5.0&#x000b1;2</td><td align="center" valign="top" charoff="50">2 (4)</td><td align="center" valign="top" charoff="50">5.0&#x000b1;2</td><td align="center" valign="top" charoff="50">&#x02014;</td><td align="center" valign="top" charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Others<sup>b</sup></td><td align="center" valign="top" charoff="50">4 (6)</td><td align="center" valign="top" charoff="50">4.0&#x000b1;1</td><td align="center" valign="top" charoff="50">&#x02014;</td><td align="center" valign="top" charoff="50">&#x02014;</td><td align="center" valign="top" charoff="50">4 (22)</td><td align="center" valign="top" charoff="50">4.0&#x000b1;1</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Overall</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">10.8&#x000b1;0.8</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">10.2&#x000b1;0.8</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">12.5&#x000b1;2.2</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote5"><label>a</label><p>LV5FU2-irinotecan, FOLFOX 4, FOLFOX 6 and FOLFOX 7 are biweekly regimens; ELOXFU 3, oxaliplatin monotherapy and other regimens are three-weekly regimens. </p></fn><fn id="tbfnote6"><label>b</label><p>One patient was treated with an association of raltitrexed and oxaliplatin, two patients with an association of capecitabine and oxaliplatin and one patient with an association of raltitrexed and irinotecan.</p></fn></table-wrap-foot></table-wrap>). Patients received oxaliplatin- or irinotecan-based regimen mainly as second-line treatment (51&#x00025;) after failure of 5-FU (<xref rid="tbl3" ref-type="table">Table 3</xref>
 <table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p content-type="table-title">Repartition of oxaliplatin or irinotecan chemotherapy line</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Chemotherapy line</bold></th><th align="left" valign="top" charoff="50"><bold>All patients, <italic>n</italic>&#x0003d;66 (&#x00025;)</bold></th><th align="left" valign="top" charoff="50"><bold>Group 1, <italic>n</italic>&#x0003d;48 (&#x00025;)</bold></th><th align="left" valign="top" charoff="50"><bold>Group 2, <italic>n</italic>&#x0003d;18 (&#x00025;)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">&#x02003;First line</td><td align="left" valign="top" charoff="50">27 (41)</td><td align="left" valign="top" charoff="50">20 (42)</td><td align="left" valign="top" charoff="50">7 (39)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Oxaliplatin</td><td align="left" valign="top" charoff="50">19</td><td align="left" valign="top" charoff="50">14</td><td align="left" valign="top" charoff="50">5</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Irinotecan</td><td align="left" valign="top" charoff="50">8</td><td align="left" valign="top" charoff="50">6</td><td align="left" valign="top" charoff="50">2</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Second line</td><td align="left" valign="top" charoff="50">34 (51)</td><td align="left" valign="top" charoff="50">26 (54)</td><td align="left" valign="top" charoff="50">8 (44)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Oxaliplatin</td><td align="left" valign="top" charoff="50">21</td><td align="left" valign="top" charoff="50">17</td><td align="left" valign="top" charoff="50">4</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Irinotecan</td><td align="left" valign="top" charoff="50">13</td><td align="left" valign="top" charoff="50">9</td><td align="left" valign="top" charoff="50">4</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Third line</td><td align="left" valign="top" charoff="50">5 (8)</td><td align="left" valign="top" charoff="50">2 (4)</td><td align="left" valign="top" charoff="50">3 (17)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Oxaliplatin</td><td align="left" valign="top" charoff="50">4</td><td align="left" valign="top" charoff="50">2</td><td align="left" valign="top" charoff="50">2</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Irinotecan</td><td align="left" valign="top" charoff="50">1</td><td align="left" valign="top" charoff="50">&#x02014;</td><td align="left" valign="top" charoff="50">1</td></tr></tbody></table></table-wrap>).</p><p>Among the 545 cycles of chemotherapy administered, 190 cycles (35&#x00025;) were carried out with a dose reduction of 126 (31&#x00025;) in group 1 and 64 (48&#x00025;) in group 2.</p></sec><sec><title>Toxicity</title><p>In all, 28 (42&#x00025;) patients experienced grade 3 and 4 toxicity (<xref rid="tbl4" ref-type="table">Table 4</xref>
 <table-wrap id="tbl4" position="float"><label>Table 4</label><caption><p content-type="table-title">Maximum toxicity per patient</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Grade 3 and 4 toxicity</bold><sup>a</sup></th><th align="center" valign="top" charoff="50"><bold>All patients, <italic>n</italic>&#x0003d;66 (&#x00025;)</bold></th><th align="center" valign="top" charoff="50"><bold>Oxaliplatin-based regimen, <italic>n</italic>&#x0003d;44 (&#x00025;)</bold></th><th align="center" valign="top" charoff="50"><bold>Irinotecan-based regimen, <italic>n</italic>&#x0003d;22 (&#x00025;)</bold></th><th align="center" valign="top" charoff="50"><bold>Group 1, <italic>n</italic>&#x0003d;48 (&#x00025;)</bold></th><th align="center" valign="top" charoff="50"><bold>Group 2, <italic>n</italic>&#x0003d;18 (&#x00025;)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Any grades 3 and 4 (except alopecia)</td><td align="center" valign="top" charoff="50">28 (42)</td><td align="center" valign="top" charoff="50">16 (36)</td><td align="center" valign="top" charoff="50">12 (54)</td><td align="center" valign="top" charoff="50">20 (42)</td><td align="center" valign="top" charoff="50">8 (44)</td></tr><tr><td align="left" valign="top" charoff="50">Neutropenia</td><td align="center" valign="top" charoff="50">11 (17)</td><td align="center" valign="top" charoff="50">6 (14)</td><td align="center" valign="top" charoff="50">5 (23)</td><td align="center" valign="top" charoff="50">8 (17)</td><td align="center" valign="top" charoff="50">3 (17)</td></tr><tr><td align="left" valign="top" charoff="50">Thrombopenia</td><td align="center" valign="top" charoff="50">4 (6)</td><td align="center" valign="top" charoff="50">4 (9)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">2 (4)</td><td align="center" valign="top" charoff="50">2 (11)</td></tr><tr><td align="left" valign="top" charoff="50">Anaemia</td><td align="center" valign="top" charoff="50">1 (1.5)</td><td align="center" valign="top" charoff="50">1 (2)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">1 (2)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Nausea and vomiting</td><td align="center" valign="top" charoff="50">5 (8)</td><td align="center" valign="top" charoff="50">3 (7)</td><td align="center" valign="top" charoff="50">2 (9)</td><td align="center" valign="top" charoff="50">4 (8)</td><td align="center" valign="top" charoff="50">1 (6)</td></tr><tr><td align="left" valign="top" charoff="50">Diarrhoea</td><td align="center" valign="top" charoff="50">10 (15)</td><td align="center" valign="top" charoff="50">4 (9)</td><td align="center" valign="top" charoff="50">6 (27)</td><td align="center" valign="top" charoff="50">7 (15)</td><td align="center" valign="top" charoff="50">2 (11)</td></tr><tr><td align="left" valign="top" charoff="50">Stomatitis</td><td align="center" valign="top" charoff="50">2 (3)</td><td align="center" valign="top" charoff="50">2 (5)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">2 (4)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Neurologic</td><td align="center" valign="top" charoff="50">7 (11)</td><td align="center" valign="top" charoff="50">7 (16)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">5 (10)</td><td align="center" valign="top" charoff="50">2 (11)</td></tr><tr><td align="left" valign="top" charoff="50">Treatment interruption for toxicity</td><td align="center" valign="top" charoff="50">11 (17)</td><td align="center" valign="top" charoff="50">8 (18)</td><td align="center" valign="top" charoff="50">3 (14)</td><td align="center" valign="top" charoff="50">9 (19)</td><td align="center" valign="top" charoff="50">2 (11)</td></tr><tr><td align="left" valign="top" charoff="50">Number of delayed cycles for toxicity&#x0002f;total number of cycles</td><td align="center" valign="top" charoff="50">38&#x0002f;545 (7)</td><td align="center" valign="top" charoff="50">24&#x0002f;309 (8)</td><td align="center" valign="top" charoff="50">14&#x0002f;236 (6)</td><td align="center" valign="top" charoff="50">27&#x0002f;411 (7)</td><td align="center" valign="top" charoff="50">11&#x0002f;134 (8)</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote7"><label>a</label><p>According to WHO grade.</p></fn></table-wrap-foot></table-wrap>). The main severe toxicities were neutropenia in 11 patients and diarrhoea in 10 patients. The toxicity pattern was similar in groups 1 and 2. Definitive treatment interruption for toxicity occurred in four of the nine (44&#x00025;) patients with a Charlson score higher than 2 and in seven of the 57 (12&#x00025;) patients with a Charlson score equal or less than 2.</p></sec><sec><title>Objective tumoral responses</title><p>Three patients (4.5&#x00025;) were not evaluable for tumoral response. Objective responses were observed in 14 patients (21&#x00025;) (<xref rid="tbl5" ref-type="table">Table 5</xref>
 <table-wrap id="tbl5" position="float"><label>Table 5</label><caption><p content-type="table-title">Tumoral responses</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50"><bold>All patients, <italic>n</italic>&#x0003d;66 (&#x00025;)</bold></th><th align="center" valign="top" charoff="50"><bold>First line, <italic>n</italic>&#x0003d;27 (&#x00025;)</bold></th><th align="center" valign="top" charoff="50"><bold>Second line, <italic>n</italic>&#x0003d;34 (&#x00025;)</bold></th><th align="center" valign="top" charoff="50"><bold>Group 1, <italic>n</italic>&#x0003d;48 (&#x00025;)</bold></th><th align="center" valign="top" charoff="50"><bold>Group 2, <italic>n</italic>&#x0003d;18 (&#x00025;)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Complete response</td><td align="center" valign="top" charoff="50">1 (1.5)</td><td align="center" valign="top" charoff="50">1 (4)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">1 (6)</td></tr><tr><td align="left" valign="top" charoff="50">Partial response</td><td align="center" valign="top" charoff="50">13 (20)</td><td align="center" valign="top" charoff="50">9 (33)</td><td align="center" valign="top" charoff="50">4 (12)</td><td align="center" valign="top" charoff="50">11 (23)</td><td align="center" valign="top" charoff="50">2 (11)</td></tr><tr><td align="left" valign="top" charoff="50">Stable disease</td><td align="center" valign="top" charoff="50">31 (47)</td><td align="center" valign="top" charoff="50">12 (44)</td><td align="center" valign="top" charoff="50">17 (50)</td><td align="center" valign="top" charoff="50">20 (42)</td><td align="center" valign="top" charoff="50">11 (61)</td></tr><tr><td align="left" valign="top" charoff="50">Progression</td><td align="center" valign="top" charoff="50">18 (27)</td><td align="center" valign="top" charoff="50">4 (15)</td><td align="center" valign="top" charoff="50">12 (35)</td><td align="center" valign="top" charoff="50">14 (29)</td><td align="center" valign="top" charoff="50">4 (22)</td></tr><tr><td align="left" valign="top" charoff="50">Not evaluable</td><td align="center" valign="top" charoff="50">3 (4.5)</td><td align="center" valign="top" charoff="50">1 (4)</td><td align="center" valign="top" charoff="50">1 (3)</td><td align="center" valign="top" charoff="50">3 (6)</td><td align="center" valign="top" charoff="50">0</td></tr></tbody></table></table-wrap>). Tumour control defined as an objective response or stabilisation was obtained in 44 patients (67&#x00025;).</p></sec><sec><title>PFS and OS</title><p>For all patients, the median PFS was 6.3 (range, 1&#x02013;30.9) months (<xref ref-type="fig" rid="fig1">Figure 1</xref><fig id="fig1"><label>Figure 1</label><caption><p>PFS curve.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="gif" xlink:href="89-6601310f1"/></fig>). PFS was 4.5 (range, 1.4&#x02013;13.2) months for group 2 patients and 7.3 (range, 1&#x02013;30.9) months for group 1 patients (<xref ref-type="fig" rid="fig2">Figure 2</xref><fig id="fig2"><label>Figure 2</label><caption><p>PFS curves according to age group.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="gif" xlink:href="89-6601310f2"/></fig>). The median OS was 11.8 (range, 1.8&#x02013;32.8) months (<xref ref-type="fig" rid="fig3">Figure 3</xref><fig id="fig3"><label>Figure 3</label><caption><p>OS curve.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="gif" xlink:href="89-6601310f3"/></fig>). The median OS was 9.9 (range, 2.3&#x02013;13.9) months for group 2 patients and 12.1 (range, 1.8&#x02013;32.8) months for group 1 patients (<xref ref-type="fig" rid="fig4">Figure 4</xref><fig id="fig4"><label>Figure 4</label><caption><p>OS curves according to age group.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="gif" xlink:href="89-6601310f4"/></fig>). The median OS from the beginning of the first-line chemotherapy was 16.7 (range, 4&#x02013;42.3) months. The survival rate from the beginning of the first-line chemotherapy was 72&#x00025; at 1 year and 34&#x00025; at 2 years.</p><p>For the 27 patients treated in first line, the median PFS was 6.8 months (range, 1&#x02013;29.2) and the median OS was 11.2 months (range, 4&#x02013;29.2). For the 34 patients treated in second line, the median PFS was 6.3 months (range, 1&#x02013;30.9) and the median OS was 11.6 months (range, 1.8&#x02013;32.8). The median OS from the beginning of the first-line chemotherapy was 20.6 months (range, 5.8&#x02013;42.3) in these 34 patients.</p></sec><sec><title>PS and weight improvement</title><p>Among the 53 patients with an initial PS &#x0003e;1, six were not evaluable for PS evolution and 15 (32&#x00025;) had a PS improvement. A total of 28&#x00025; of all the patients had a gain in weight during the treatment.</p></sec></sec><sec><title>DISCUSSION</title><p>This is the first study of tolerance and efficacy of oxaliplatin- and irinotecan-based chemotherapy in elderly patients. Our results show that oxaliplatin- or irinotecan-based chemotherapy in elderly patients is feasible and safe.</p><p>A total of 42&#x00025; of the patients experienced severe toxicity without treatment-related death. Previous retrospective studies evaluating 5-FU&#x0002b;leucovorin regimens in an elderly population reported severe toxicity in 20&#x00025; of patients treated with the LV5FU2 regimen (<xref ref-type="other" rid="bib14">Mabro <italic>et al</italic>, 1999</xref>) and in 58&#x00025; of patients treated with the 5-FU bolus regimen (<xref ref-type="other" rid="bib22">Stein <italic>et al</italic>, 1995</xref>). We report severe neutropenia in 14 and 23&#x00025; of patients treated with oxaliplatin and irinotecan, respectively. Previous studies in nonelderly patients reported severe neutropenia in 36&#x02013;41&#x00025; (<xref ref-type="other" rid="bib1">Andre <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib7">de Gramont <italic>et al</italic>, 2000</xref>) with oxaliplatin and 29&#x02013;54&#x00025; (<xref ref-type="other" rid="bib9">Douillard <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib20">Saltz <italic>et al</italic>, 2000</xref>) with irinotecan. In our study, severe neuropathy occurred in 16&#x00025; of patients treated with oxaliplatin; previous studies reported severed neuropathy in 18 and 20&#x00025; (<xref ref-type="other" rid="bib1">Andre <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib7">de Gramont <italic>et al</italic>, 2000</xref>). Severe diarrhoea occurred in 27&#x00025; of patients treated with irinotecan. Previous studies reported severe diarrhoea in 22&#x02013;44&#x00025; (<xref ref-type="other" rid="bib9">Douillard <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib20">Saltz <italic>et al</italic>, 2000</xref>). A full dose of chemotherapy was administered in 65&#x00025; of the cycles. Previous studies in nonelderly patients reported a dose intensity of 73&#x00025; for oxaliplatin (<xref ref-type="other" rid="bib7">de Gramont <italic>et al</italic>, 2000</xref>) and 72&#x02013;93&#x00025; for irinotecan (<xref ref-type="other" rid="bib9">Douillard <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib20">Saltz <italic>et al</italic>, 2000</xref>) in first-line chemotherapy. The frequent dose reduction observed in our report, especially in group 2, could partly explain the mild toxicity.</p><p>The overall objective response rate was 22&#x00025;; 38&#x00025; in first-line treatment. The response rates reported in previous studies in elderly patients treated with a 5-FU- or raltitrexed-based regimen were 18&#x00025; (<xref ref-type="other" rid="bib5">Chiara <italic>et al</italic>, 1998</xref>), 22&#x00025; (<xref ref-type="other" rid="bib11">Feliu <italic>et al</italic>, 2002</xref>), 24&#x00025; (<xref ref-type="other" rid="bib18">Popescu <italic>et al</italic>, 1999</xref>), 26&#x00025; (<xref ref-type="other" rid="bib15">Magne <italic>et al</italic>, 2002</xref>) and 44&#x00025; (<xref ref-type="other" rid="bib14">Mabro <italic>et al</italic>, 1999</xref>). The response rate in nonelderly patients treated in first line with an oxaliplatin- or irinotecan-based regimen is about 50&#x00025; (<xref ref-type="other" rid="bib7">de Gramont <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib9">Douillard <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib20">Saltz <italic>et al</italic>, 2000</xref>). In second line, the response rates ranged from 17&#x00025; (<xref ref-type="other" rid="bib19">Rougier <italic>et al</italic>, 1997</xref>) to 46&#x00025; (<xref ref-type="other" rid="bib8">de Gramont <italic>et al</italic>, 1997</xref>). The response rates observed in our study in first-line treatment seem to be higher than those generally obtained with 5-FU alone in elderly patients and comparable to those obtained with oxaliplatin or irinotecan in nonelderly patients. In second line, the response rates seem to be lower than those published with oxaliplatin or irinotecan in nonelderly patients.</p><p>We observed a median OS of 11.2 months in first line. It was 9.6 (<xref ref-type="other" rid="bib11">Feliu <italic>et al</italic>, 2002</xref>), 9.7 (<xref ref-type="other" rid="bib18">Popescu <italic>et al</italic>, 1999</xref>), 16.4 (<xref ref-type="other" rid="bib14">Mabro <italic>et al</italic>, 1999</xref>) and 14 months (<xref ref-type="other" rid="bib15">Magne <italic>et al</italic>, 2002</xref>) in previous studies where elderly patients were treated with a 5-FU- or raltitrexed-based regimen. Nevertheless, although we did not observe a better OS with oxaliplatin or irinotecan than in previous studies with 5-FU or raltitrexed, it must be pointed out that in all these studies the median age was younger and only few patients over 79 years were considered. We have suggested that age over 79 years is associated with poor survival. This population represents 27&#x00025; of the patients in our study and could explain the poor OS observed. Nevertheless, the survival observed in our elderly patients is poorer than the one reported in prospective studies in younger patients in first-line treatment (<xref ref-type="other" rid="bib7">de Gramont <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib9">Douillard <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib20">Saltz <italic>et al</italic>, 2000</xref>). In patients treated in second line with oxaliplatin or irinotecan, we observed an 11.6 month median survival from the beginning of second line and a 20.6 month median survival from the beginning of first line. These data prompted us to use a second-line chemotherapy in the elderly after first-line failure. Nevertheless, the discrepancy between OS of patients treated in first line with oxaliplatin or irinotecan and OS from the beginning of chemotherapy in patients treated in second line with oxaliplatin or irinotecan suggest that tumours of patients treated in second line had a slower growth rate.</p><p>The median PFS in first line was 6.8 months, which is comparable with PFS reported in younger patients: 9 months with oxaliplatin (<xref ref-type="other" rid="bib7">de Gramont <italic>et al</italic>, 2000</xref>) and 6.7&#x02013;7 months with irinotecan (<xref ref-type="other" rid="bib9">Douillard <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib20">Saltz <italic>et al</italic>, 2000</xref>). An improvement of PS was noted in 32&#x00025; of the patients with initial degraded PS; this is comparable with the 42&#x00025; of improvement of PS reported with oxaliplatin in younger patients (<xref ref-type="other" rid="bib7">de Gramont <italic>et al</italic>, 2000</xref>). In elderly patients treated with 5-FU alone, PS improvement varied from 26 to 56&#x00025; (<xref ref-type="other" rid="bib14">Mabro <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib15">Magne <italic>et al</italic>, 2002</xref>). Nevertheless, it is necessary to evaluate the influence of chemotherapy on quality of life and patient autonomy in a prospective study on elderly patients. In our study, the majority of the patients had no or little severe comorbidity. This suggests that the population is selected. This is the first study using the Charlson comorbidity score for elderly patients treated for metastatic colorectal carcinoma. A prognostic value of Charlson &#x0003e;2 was suggested for the occurrence of definitive treatment interruption for toxicity. A stratification according to the Charlson comorbidity score should be considered in prospective studies in elderly patients.</p><p>We conclude that chemotherapy with oxaliplatin or irinotecan in selected elderly patients is feasible with manageable toxicity. Improvements of PS and prolonged PFS and OS were obtained, but the benefit is weaker after 79 years. Moreover, second-line chemotherapy should be considered whenever it is possible in elderly patients. Prospective studies are needed to establish the benefit of the different chemotherapy regimens for quality of life and autonomy in elderly patients.</p></sec></body><back><ref-list><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andre</surname><given-names>T</given-names></name><name><surname>Bensmaine</surname><given-names>MA</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Francois</surname><given-names>E</given-names></name><name><surname>Lucas</surname><given-names>V</given-names></name><name><surname>Desseigne</surname><given-names>F</given-names></name><name><surname>Beerblock</surname><given-names>K</given-names></name><name><surname>Bouche</surname><given-names>O</given-names></name><name><surname>Carola</surname><given-names>E</given-names></name><name><surname>Merrouche</surname><given-names>Y</given-names></name><name><surname>Morvan</surname><given-names>F</given-names></name><name><surname>Dupont-Andre</surname><given-names>G</given-names></name><name><surname>de Gramont</surname><given-names>A</given-names></name></person-group><article-title>Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen</article-title><source>J Clin Oncol</source><year>1999</year><volume>17</volume><fpage>3560</fpage><lpage>3568</lpage><!--PubMed citation query: 'J Clin Oncol||17|3560||bib1|'--><pub-id pub-id-type="pmid">10550155</pub-id></citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beretta</surname><given-names>G</given-names></name><name><surname>Bolina</surname><given-names>R</given-names></name><name><surname>Cozzi</surname><given-names>C</given-names></name></person-group><article-title>Should we consider the weekly (w) chemotherapy (CT) with fluorouracil (F)&#x0002b;racemic folinic acid (f) a standard treatment for advanced&#x0002f;metastatic carcinoma of digestive tract (DTC) in elderly patients (pts)</article-title><source>Proc Am Soc Clin Oncol</source><year>1997</year><volume>16</volume><fpage>259a</fpage><!--PubMed citation query: 'Proc Am Soc Clin Oncol||16|259a||bib2|'--></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Sankila</surname><given-names>R</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Parkin</surname><given-names>DM</given-names></name></person-group><article-title>Estimates of cancer incidence and mortality in Europe in 1995</article-title><source>Eur J Cancer</source><year>2002</year><volume>38</volume><fpage>99</fpage><lpage>166</lpage><!--PubMed citation query: 'Eur J Cancer||38|99||bib3|'--><pub-id pub-id-type="pmid">11750846</pub-id></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Charlson</surname><given-names>ME</given-names></name><name><surname>Pompei</surname><given-names>P</given-names></name><name><surname>Ales</surname><given-names>KL</given-names></name><name><surname>MacKenzie</surname><given-names>CR</given-names></name></person-group><article-title>A new method of classifying prognostic comorbidity in longitudinal studies: development and validation</article-title><source>J Chronic Dis</source><year>1987</year><volume>40</volume><fpage>373</fpage><lpage>383</lpage><!--PubMed citation query: 'J Chronic Dis||40|373||bib4|'--><pub-id pub-id-type="pmid">3558716</pub-id></citation></ref><ref id="bib5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chiara</surname><given-names>S</given-names></name><name><surname>Nobile</surname><given-names>MT</given-names></name><name><surname>Vincenti</surname><given-names>M</given-names></name><name><surname>Lionetto</surname><given-names>R</given-names></name><name><surname>Gozza</surname><given-names>A</given-names></name><name><surname>Barzacchi</surname><given-names>MC</given-names></name><name><surname>Sanguineti</surname><given-names>O</given-names></name><name><surname>Repetto</surname><given-names>L</given-names></name><name><surname>Rosso</surname><given-names>R</given-names></name></person-group><article-title>Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy</article-title><source>Cancer Chemother Pharmacol</source><year>1998</year><volume>42</volume><fpage>336</fpage><lpage>340</lpage><!--PubMed citation query: 'Cancer Chemother Pharmacol||42|336||bib5|'--><pub-id pub-id-type="pmid">9744780</pub-id></citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Pyrhonen</surname><given-names>S</given-names></name><name><surname>James</surname><given-names>RD</given-names></name><name><surname>Punt</surname><given-names>CJ</given-names></name><name><surname>Hickish</surname><given-names>TF</given-names></name><name><surname>Heikkila</surname><given-names>R</given-names></name><name><surname>Johannesen</surname><given-names>TB</given-names></name><name><surname>Starkhammar</surname><given-names>H</given-names></name><name><surname>Topham</surname><given-names>CA</given-names></name><name><surname>Awad</surname><given-names>L</given-names></name><name><surname>Jacques</surname><given-names>C</given-names></name><name><surname>Herait</surname><given-names>P</given-names></name></person-group><article-title>Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer</article-title><source>Lancet</source><year>1998</year><volume>352</volume><fpage>1413</fpage><lpage>1418</lpage><!--PubMed citation query: 'Lancet||352|1413||bib6|'--><pub-id pub-id-type="pmid">9807987</pub-id></citation></ref><ref id="bib7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Gramont</surname><given-names>A</given-names></name><name><surname>Figer</surname><given-names>A</given-names></name><name><surname>Seymour</surname><given-names>M</given-names></name><name><surname>Homerin</surname><given-names>M</given-names></name><name><surname>Hmissi</surname><given-names>A</given-names></name><name><surname>Cassidy</surname><given-names>J</given-names></name><name><surname>Boni</surname><given-names>C</given-names></name><name><surname>Cortes-Funes</surname><given-names>H</given-names></name><name><surname>Cervantes</surname><given-names>A</given-names></name><name><surname>Freyer</surname><given-names>G</given-names></name><name><surname>Papamichael</surname><given-names>D</given-names></name><name><surname>Le Bail</surname><given-names>N</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Hendler</surname><given-names>D</given-names></name><name><surname>de Braud</surname><given-names>F</given-names></name><name><surname>Wilson</surname><given-names>C</given-names></name><name><surname>Morvan</surname><given-names>F</given-names></name><name><surname>Bonetti</surname><given-names>A</given-names></name></person-group><article-title>Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>2938</fpage><lpage>2947</lpage><!--PubMed citation query: 'J Clin Oncol||18|2938||bib7|'--><pub-id pub-id-type="pmid">10944126</pub-id></citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Gramont</surname><given-names>A</given-names></name><name><surname>Vignoud</surname><given-names>J</given-names></name><name><surname>Tournigand</surname><given-names>C</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Andre</surname><given-names>T</given-names></name><name><surname>Varette</surname><given-names>C</given-names></name><name><surname>Raymond</surname><given-names>E</given-names></name><name><surname>Moreau</surname><given-names>S</given-names></name><name><surname>Le Bail</surname><given-names>N</given-names></name><name><surname>Krulik</surname><given-names>M</given-names></name></person-group><article-title>Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer</article-title><source>Eur J Cancer</source><year>1997</year><volume>33</volume><fpage>214</fpage><lpage>219</lpage><!--PubMed citation query: 'Eur J Cancer||33|214||bib8|'--><pub-id pub-id-type="pmid">9135491</pub-id></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Roth</surname><given-names>AD</given-names></name><name><surname>Navarro</surname><given-names>M</given-names></name><name><surname>James</surname><given-names>RD</given-names></name><name><surname>Karasek</surname><given-names>P</given-names></name><name><surname>Jandik</surname><given-names>P</given-names></name><name><surname>Iveson</surname><given-names>T</given-names></name><name><surname>Carmichael</surname><given-names>J</given-names></name><name><surname>Alakl</surname><given-names>M</given-names></name><name><surname>Gruia</surname><given-names>G</given-names></name><name><surname>Awad</surname><given-names>L</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name></person-group><article-title>Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial</article-title><source>Lancet</source><year>2000</year><volume>355</volume><fpage>1041</fpage><lpage>1047</lpage><!--PubMed citation query: 'Lancet||355|1041||bib9|'--><pub-id pub-id-type="pmid">10744089</pub-id></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ducreux</surname><given-names>M</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name><name><surname>Polus</surname><given-names>M</given-names></name><name><surname>Ould Kaci</surname><given-names>M</given-names></name><name><surname>Ychou</surname><given-names>M</given-names></name><name><surname>Conroy</surname><given-names>T</given-names></name></person-group><article-title>R&#x000e9;sultats de l'association oxaliplatine-LV5FU2 toutes les 3 semaines dans les cancers colorectaux avanc&#x000e9;s progressant sous 5FU</article-title><source>Gastroent&#x000e9;rol Clin Biol</source><year>1999</year><volume>23</volume><fpage>A108</fpage><!--PubMed citation query: 'Gastroent&#x000e9;rol Clin Biol||23|A108||bib10|'--></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feliu</surname><given-names>J</given-names></name><name><surname>Mel</surname><given-names>JR</given-names></name><name><surname>Camps</surname><given-names>C</given-names></name><name><surname>Escudero</surname><given-names>P</given-names></name><name><surname>Aparicio</surname><given-names>J</given-names></name><name><surname>Menendez</surname><given-names>D</given-names></name><name><surname>Garcia</surname><given-names>GC</given-names></name><name><surname>Rodriguez</surname><given-names>MR</given-names></name><name><surname>Sanchez</surname><given-names>JJ</given-names></name><name><surname>Gonzalez</surname><given-names>BM</given-names></name></person-group><article-title>Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen</article-title><source>Eur J Cancer</source><year>2002</year><volume>38</volume><fpage>1204</fpage><lpage>1211</lpage><!--PubMed citation query: 'Eur J Cancer||38|1204||bib11|'--><pub-id pub-id-type="pmid">12044507</pub-id></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gatta</surname><given-names>G</given-names></name><name><surname>Faivre</surname><given-names>J</given-names></name><name><surname>Capocaccia</surname><given-names>R</given-names></name><name><surname>Ponz</surname><given-names>dL</given-names></name></person-group><article-title>Survival of colorectal cancer patients in Europe during the period 1978&#x02013;1989. EUROCARE Working Group</article-title><source>Eur J Cancer</source><year>1998</year><volume>34</volume><fpage>2176</fpage><lpage>2183</lpage><!--PubMed citation query: 'Eur J Cancer||34|2176||bib12|'--></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kohne</surname><given-names>CH</given-names></name><name><surname>Grothey</surname><given-names>A</given-names></name><name><surname>Bokemeyer</surname><given-names>C</given-names></name><name><surname>Bontke</surname><given-names>N</given-names></name><name><surname>Aapro</surname><given-names>M</given-names></name></person-group><article-title>Chemotherapy in elderly patients with colorectal cancer</article-title><source>Ann Oncol</source><year>2001</year><volume>12</volume><fpage>435</fpage><lpage>442</lpage><!--PubMed citation query: 'Ann Oncol||12|435||bib13|'--><pub-id pub-id-type="pmid">11398873</pub-id></citation></ref><ref id="bib14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mabro</surname><given-names>M</given-names></name><name><surname>Gilles-Amar</surname><given-names>V</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Carola</surname><given-names>E</given-names></name><name><surname>Maindrault-Goebel</surname><given-names>F</given-names></name><name><surname>de Gramont</surname><given-names>A</given-names></name><name><surname>Krulik</surname><given-names>M</given-names></name></person-group><article-title>Bimonthly 5-fluorouracil in elderly patients with metastatic colorectal cancer study of 50 patients</article-title><source>Rev Med Intern</source><year>1999</year><volume>20</volume><fpage>863</fpage><lpage>868</lpage><!--PubMed citation query: 'Rev Med Intern||20|863||bib14|'--></citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Magne</surname><given-names>N</given-names></name><name><surname>Francois</surname><given-names>E</given-names></name><name><surname>Broisin</surname><given-names>L</given-names></name><name><surname>Guardiola</surname><given-names>E</given-names></name><name><surname>Ramaioli</surname><given-names>A</given-names></name><name><surname>Ferrero</surname><given-names>JM</given-names></name><name><surname>Namer</surname><given-names>M</given-names></name></person-group><article-title>Palliative 5-fluorouracil-based chemotherapy for advanced colorectal cancer in the elderly: results of a 10-year experience</article-title><source>Am J Clin Oncol</source><year>2002</year><volume>25</volume><fpage>126</fpage><lpage>130</lpage><!--PubMed citation query: 'Am J Clin Oncol||25|126||bib15|'--><pub-id pub-id-type="pmid">11943888</pub-id></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maindrault-Goebel</surname><given-names>F</given-names></name><name><surname>de Gramont</surname><given-names>A</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Andre</surname><given-names>T</given-names></name><name><surname>Carola</surname><given-names>E</given-names></name><name><surname>Gilles</surname><given-names>V</given-names></name><name><surname>Lotz</surname><given-names>JP</given-names></name><name><surname>Tournigand</surname><given-names>C</given-names></name><name><surname>Mabro</surname><given-names>M</given-names></name><name><surname>Molitor</surname><given-names>JL</given-names></name><name><surname>Artru</surname><given-names>P</given-names></name><name><surname>Izrael</surname><given-names>V</given-names></name><name><surname>Krulik</surname><given-names>M</given-names></name></person-group><article-title>Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR)</article-title><source>Ann Oncol</source><year>2000</year><volume>11</volume><fpage>1477</fpage><lpage>1483</lpage><!--PubMed citation query: 'Ann Oncol||11|1477||bib16|'--><pub-id pub-id-type="pmid">11142489</pub-id></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maindrault-Goebel</surname><given-names>F</given-names></name><name><surname>de Gramont</surname><given-names>A</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Andre</surname><given-names>T</given-names></name><name><surname>Carola</surname><given-names>E</given-names></name><name><surname>Mabro</surname><given-names>M</given-names></name><name><surname>Artru</surname><given-names>P</given-names></name><name><surname>Gilles</surname><given-names>V</given-names></name><name><surname>Lotz</surname><given-names>JP</given-names></name><name><surname>Izrael</surname><given-names>V</given-names></name><name><surname>Krulik</surname><given-names>M</given-names></name></person-group><article-title>High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)</article-title><source>Eur J Cancer</source><year>2001</year><volume>37</volume><fpage>1000</fpage><lpage>1005</lpage><!--PubMed citation query: 'Eur J Cancer||37|1000||bib17|'--><pub-id pub-id-type="pmid">11334725</pub-id></citation></ref><ref id="bib18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Popescu</surname><given-names>RA</given-names></name><name><surname>Norman</surname><given-names>A</given-names></name><name><surname>Ross</surname><given-names>PJ</given-names></name><name><surname>Parikh</surname><given-names>B</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name></person-group><article-title>Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older</article-title><source>J Clin Oncol</source><year>1999</year><volume>17</volume><fpage>2412</fpage><lpage>2418</lpage><!--PubMed citation query: 'J Clin Oncol||17|2412||bib18|'--><pub-id pub-id-type="pmid">10561304</pub-id></citation></ref><ref id="bib19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rougier</surname><given-names>P</given-names></name><name><surname>Bugat</surname><given-names>R</given-names></name><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Culine</surname><given-names>S</given-names></name><name><surname>Suc</surname><given-names>E</given-names></name><name><surname>Brunet</surname><given-names>P</given-names></name><name><surname>Becouarn</surname><given-names>Y</given-names></name><name><surname>Ychou</surname><given-names>M</given-names></name><name><surname>Marty</surname><given-names>M</given-names></name><name><surname>Extra</surname><given-names>JM</given-names></name><name><surname>Bonneterre</surname><given-names>J</given-names></name><name><surname>Adenis</surname><given-names>A</given-names></name><name><surname>Seitz</surname><given-names>JF</given-names></name><name><surname>Ganem</surname><given-names>G</given-names></name><name><surname>Namer</surname><given-names>M</given-names></name><name><surname>Conroy</surname><given-names>T</given-names></name><name><surname>Negrier</surname><given-names>S</given-names></name><name><surname>Merrouche</surname><given-names>Y</given-names></name><name><surname>Burki</surname><given-names>F</given-names></name><name><surname>Mousseau</surname><given-names>M</given-names></name><name><surname>Herait</surname><given-names>P</given-names></name><name><surname>Mahjoubi</surname><given-names>M</given-names></name></person-group><article-title>Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy</article-title><source>J Clin Oncol</source><year>1997</year><volume>15</volume><fpage>251</fpage><lpage>260</lpage><!--PubMed citation query: 'J Clin Oncol||15|251||bib19|'--><pub-id pub-id-type="pmid">8996150</pub-id></citation></ref><ref id="bib20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saltz</surname><given-names>LB</given-names></name><name><surname>Cox</surname><given-names>JV</given-names></name><name><surname>Blanke</surname><given-names>C</given-names></name><name><surname>Rosen</surname><given-names>LS</given-names></name><name><surname>Fehrenbacher</surname><given-names>L</given-names></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Maroun</surname><given-names>JA</given-names></name><name><surname>Ackland</surname><given-names>SP</given-names></name><name><surname>Locker</surname><given-names>PK</given-names></name><name><surname>Pirotta</surname><given-names>N</given-names></name><name><surname>Elfring</surname><given-names>GL</given-names></name><name><surname>Miller</surname><given-names>LL</given-names></name></person-group><article-title>Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><fpage>905</fpage><lpage>914</lpage><!--PubMed citation query: 'N Engl J Med||343|905||bib20|'--><pub-id pub-id-type="pmid">11006366</pub-id></citation></ref><ref id="bib21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sargent</surname><given-names>DJ</given-names></name><name><surname>Goldberg</surname><given-names>RM</given-names></name><name><surname>Jacobson</surname><given-names>SD</given-names></name><name><surname>Macdonald</surname><given-names>JS</given-names></name><name><surname>Labianca</surname><given-names>R</given-names></name><name><surname>Haller</surname><given-names>DG</given-names></name><name><surname>Shepherd</surname><given-names>LE</given-names></name><name><surname>Seitz</surname><given-names>JF</given-names></name><name><surname>Francini</surname><given-names>G</given-names></name></person-group><article-title>A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients</article-title><source>N Engl J Med</source><year>2001</year><volume>345</volume><fpage>1091</fpage><lpage>1097</lpage><!--PubMed citation query: 'N Engl J Med||345|1091||bib21|'--><pub-id pub-id-type="pmid">11596588</pub-id></citation></ref><ref id="bib22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>BN</given-names></name><name><surname>Petrelli</surname><given-names>NJ</given-names></name><name><surname>Douglass</surname><given-names>HO</given-names></name><name><surname>Driscoll</surname><given-names>DL</given-names></name><name><surname>Arcangeli</surname><given-names>G</given-names></name><name><surname>Meropol</surname><given-names>NJ</given-names></name></person-group><article-title>Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of large scale phase III trial</article-title><source>Cancer</source><year>1995</year><volume>75</volume><fpage>11</fpage><lpage>17</lpage><!--PubMed citation query: 'Cancer||75|11||bib22|'--><pub-id pub-id-type="pmid">7804963</pub-id></citation></ref><ref id="bib23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trimble</surname><given-names>EL</given-names></name><name><surname>Carter</surname><given-names>CL</given-names></name><name><surname>Cain</surname><given-names>D</given-names></name><name><surname>Freidlin</surname><given-names>B</given-names></name><name><surname>Ungerleider</surname><given-names>RS</given-names></name><name><surname>Friedman</surname><given-names>MA</given-names></name></person-group><article-title>Representation of older patients in cancer treatment trials</article-title><source>Cancer</source><year>1994</year><volume>74</volume><fpage>2208</fpage><lpage>2214</lpage><!--PubMed citation query: 'Cancer||74|2208||bib23|'--><pub-id pub-id-type="pmid">8087794</pub-id></citation></ref></ref-list></back></article>


